NEW YORK, NY, UNITED STATES, April 1, 2026 /EINPresswire.com/ -- Çimsa, a subsidiary of Sabancı Holding and one of the ...

Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission ...

PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy delivered superior progression-free ...

From Feb. 23-27, Alabama students can apply to lots of colleges around the state for free. As part of the Alabama College Application Campaign, universities and colleges across the state and region ...

Application diversification reveals technological breadth. Electrical and electronics consuming approximately 28% of advanced ceramics, automotive applications 22%, machinery and tooling 18%, energy ...

Iberdomide has the potential to be the first approved CELMoD agent The U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date ...

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab ...

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the U.S. Food and Drug Administration ...

The U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of August 17, 2026 Bristol Myers Squibb (NYSE: BMY) today announced ...